• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.超越前线：胰腺癌维持治疗的新兴数据。
J Clin Oncol. 2021 Oct 10;39(29):3199-3206. doi: 10.1200/JCO.21.01510. Epub 2021 Aug 24.
2
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.一线治疗胰腺导管腺癌的脂质体伊立替康联合奥沙利铂、5-氟尿嘧啶和亚叶酸（NALIRIFOX）：一项 I/II 期研究。
Eur J Cancer. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4.
3
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.一线 FOLFIRINOX 方案与吉西他滨联合 nab-紫杉醇化疗治疗局限性胰腺导管腺癌的反应和生存情况。
JAMA Surg. 2020 Sep 1;155(9):832-839. doi: 10.1001/jamasurg.2020.2286.
4
Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.三种恶病质表型及在 FOLFIRINOX 治疗胰腺癌中仅脂肪丢失对生存的影响。
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):673-684. doi: 10.1002/jcsm.12307. Epub 2018 Jul 5.
5
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.TSC2 和 SMAD4 突变患者的胰腺癌免疫治疗成功：病例报告。
Front Immunol. 2021 Nov 22;12:785400. doi: 10.3389/fimmu.2021.785400. eCollection 2021.
6
Response in mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX.携带突变的转移性胰腺腺癌患者接受 FOLFIRINOX 治疗的反应。
BMJ Case Rep. 2022 Apr 29;15(4):e249370. doi: 10.1136/bcr-2022-249370.
7
Spontaneous regression of pancreatic cancer with liver metastases.伴有肝转移的胰腺癌自发消退
BMJ Case Rep. 2019 May 31;12(5):e229619. doi: 10.1136/bcr-2019-229619.
8
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.吉西他滨治疗后晚期胰腺癌患者-奥沙利铂和/或伊立替康含药方案的随机试验比较评价。
Cancer Treat Rev. 2016 Nov;50:142-147. doi: 10.1016/j.ctrv.2016.09.001. Epub 2016 Sep 9.
9
FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.氟尿嘧啶、亚叶酸钙和奥沙利铂联合方案治疗胰腺癌腹膜转移患者：一项回顾性研究。
Curr Oncol. 2019 Aug;26(4):e466-e472. doi: 10.3747/co.26.4903. Epub 2019 Aug 1.
10
When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.可治愈性潜在胰腺癌围手术期治疗的时机、内容及原因
J Clin Oncol. 2017 Feb 10;35(5):485-489. doi: 10.1200/JCO.2016.70.2134. Epub 2016 Dec 28.

引用本文的文献

1
Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.胰腺癌的维持治疗：一种基于新型药物 GP-2250（米塞替胺）与吉西他滨协同作用的新方法
Cancers (Basel). 2024 Jul 22;16(14):2612. doi: 10.3390/cancers16142612.
2
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer.一个巴掌拍不响：循环中的转化生长因子-β和程序性死亡配体-1对胰腺癌的潜在预后影响
Life (Basel). 2022 Jun 26;12(7):960. doi: 10.3390/life12070960.
3
The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.CA19-9与胆红素比值在胰腺癌、远端胆管癌及壶腹周围良性疾病患者中的诊断价值：一种新方法
Cancers (Basel). 2022 Jan 11;14(2):344. doi: 10.3390/cancers14020344.

本文引用的文献

1
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.评估转移性胰腺癌一线两种序贯治疗的随机II期试验：PANOPTIMOX-PRODIGE 35试验结果
J Clin Oncol. 2021 Oct 10;39(29):3242-3250. doi: 10.1200/JCO.20.03329. Epub 2021 Jul 21.
2
Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in Wild-Type Pancreatic Cancer.鉴定可靶向的基因融合和结构重排，以促进野生型胰腺癌的精准医疗。
JCO Precis Oncol. 2021 Jan 11;5. doi: 10.1200/PO.20.00265. eCollection 2021.
3
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.奥拉帕利辅助治疗 - 或 - 突变型乳腺癌患者。
N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.
4
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.FOLFIRINOX 与吉西他滨加 nab-紫杉醇（含序贯治疗）治疗转移性胰腺癌的比较：倾向评分匹配分析。
BMC Cancer. 2021 May 11;21(1):537. doi: 10.1186/s12885-021-08277-7.
5
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or .铂敏感的晚期胰腺癌且存在种系或体细胞致病变体的患者中，维持使用鲁卡帕尼的II期研究。 （注：原文中“in , , or .”部分内容缺失，以上是按完整句子结构翻译的大致内容）
J Clin Oncol. 2021 Aug 1;39(22):2497-2505. doi: 10.1200/JCO.21.00003. Epub 2021 May 10.
6
Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.奥拉帕利单药治疗伴有除胚系 BRCA 变异以外的 DNA 损伤修复基因改变的既往治疗过的胰腺导管腺癌：来自 2 项 2 期非随机临床试验的结果。
JAMA Oncol. 2021 May 1;7(5):693-699. doi: 10.1001/jamaoncol.2021.0006.
7
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.同源重组缺陷型胰腺导管腺癌的基因组特征与分类。
Gastroenterology. 2021 May;160(6):2119-2132.e9. doi: 10.1053/j.gastro.2021.01.220. Epub 2021 Jan 30.
8
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
9
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.靶向 KRAS(G12C)：从抑制机制到调节患者的抗肿瘤作用。
Cell. 2020 Nov 12;183(4):850-859. doi: 10.1016/j.cell.2020.09.044. Epub 2020 Oct 15.
10
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.基因组方法鉴定胰腺导管腺癌同源重组缺陷并优化治疗选择。
Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. doi: 10.1158/1078-0432.CCR-20-0418. Epub 2020 May 22.

Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Brigham and Women's Hospital, Boston, MA.

出版信息

J Clin Oncol. 2021 Oct 10;39(29):3199-3206. doi: 10.1200/JCO.21.01510. Epub 2021 Aug 24.

DOI:10.1200/JCO.21.01510
PMID:34428095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8500570/
Abstract
摘要